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ABSTRACT
Background. In breast cancer surgery, intraoperative
frozen section (FS) analysis of sentinel lymph nodes
(SLNs) enables axillary lymph node dissection (ALND)
during the same operative procedure. In case of discor-
dance between a ‘‘negative’’ FS analysis and deﬁnitive
histology, an ALND as a second operation is advocated
since additional lymph node metastases may be present.
The clinical implications of the subsequent ALND in these
patients were evaluated.
Materials and Methods. Between November 2000 and
May 2008, 879 consecutive breast cancer patients under-
went surgery including sentinel lymph node biopsy
(SLNB) with intraoperative FS analysis of 2 central cuts
from axillary SLNs. Following ﬁxation and serial section-
ing, SLNs were further examined postoperatively with
hematoxylin and eosin (H&E) and immunohistochemical
techniques. For patients with a discordant FS examination,
the effect of the pathology ﬁndings of the subsequent
ALND specimen on subsequent nonsurgical therapy were
evaluated.
Results. FS analysis detected axillary metastases in the
SLN(s) in 200 patients (23%), while the deﬁnitive pathol-
ogy examination detected metastases in SLNs in another
151 patients (17%). A complementary ALND was
performed in 108 of the 151 patients with discordant FS.
Additional tumor positive axillary lymph nodes were found
in 17 patients (16%), leading to ‘‘upstaging’’ in 7 (6%).
Subsequent nonsurgical treatment was adjusted in 4
patients (4%): all 4 had more extensive locoregional
radiotherapy; no patient received additional hormonal and/
or chemotherapy.
Conclusion. Discordance between intraoperative FS
analysis and deﬁnitive histology of SLNs is common. In
this selection of patients, a substantial proportion had
additional lymph node metastases, but postsurgical treat-
ment was rarely adjusted based on the ﬁndings of the
complementary ALND.
Sentinel lymph node biopsy (SLNB) has replaced axil-
lary lymph node dissection (ALND) for assessing axillary
lymph node status in breast cancer patients.
1,2 Subsequent
ALND is done only when the SLN contains metastases
because of the risk of additional lymph node metastases in
the non-SLNs in the axilla.
3,4
Intraoperative frozen section (FS) analysis of axillary
SLNs enables prompt detection of lymph node metastases.
As a result, ALND can be done during the same operative
procedure. Despite a ‘‘negative’’ FS result, deﬁnitive
pathology examination of the SLN will reveal metastases
in a number of patients, inherent to the more extensive
workup of lymph nodes by serial sectioning and immu-
nohistochemical techniques. In these patients, because of
the risk of additional metastases in non-SLNs, an ALND as
a second operative procedure is considered necessary for 2
reasons: locoregional control of the axilla and the
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inﬂuence subsequent nonsurgical therapy.
In a prospective cohort of breast cancer patients staged
by SLNB and with the routine use of intraoperative FS
analysis we assessed the proportion of patients in whom
intraoperative FS analysis revealed no metastases while the
deﬁnitive pathology examination did detect metastases. In
these patients, the clinical implications of a ‘‘postponed’’
ALND were evaluated.
PATIENTS AND METHODS
Between November 2000 and May 2008, data were
collected prospectively regarding 1004 consecutive
patients who underwent surgical treatment using SLNB as
a staging procedure for clinically staged T1–2N0 breast
cancer. For the present study, patients were selected who
underwent FS analysis of axillary SLNs.
The study group consisted of 879 patients since 125
patients did not undergo FS analysis and were therefore
excluded from further analysis. Reasons for not performing
FS analysis of SLNs were: small size of the SLNs, that is,
when the pathologists deemed the SLNs to small or to fatty
for reliable FS analysis (n = 64), the introduction of this
new staging technique when SLNB was followed by
ALND on a routine basis (n = 30), clinical trial partici-
pation obviating ALND (assignment to the radiotherapy
arm of the AMAROS trial, n = 26), or inability to retrieve
a visualized axillary SLN (n = 5; the surgical success rate
of SLN retrieval was 99.4%).
5
For the SLNB a 1-day protocol was used. The visuali-
zation and identiﬁcation of SLNs consisted of preoperative
lymphoscintigraphy and the intraoperative use of a c-ray
detection probe together with patent blue dye (Bleu patente ´
V, Laboratoire Guerbet, Aulnay-sous-Bois, France). Injec-
tions were given peritumorally and subcutaneously directly
above the tumor. In nonpalpable breast tumors injections
were guided by an ultrasound probe or a radiologically
placed wire. Imaging was done directly after the nanocol-
loid injection and 2 h later. In the afternoon of the same day
patients were operated on. Axillary SLNs were retrieved
ﬁrst and sent for FS analysis. Subsequently, internal mam-
mary (IM) SLNs were collected when visualized on
preoperative lymphoscintigraphy. These internal mammary
SLNs were not sent for FS analysis. Detailed information
about this procedure was published previously.
6
In the pathology department the SLNs were isolated
from fatty tissue, bisected longitudinally, separately for-
malin-ﬁxed, parafﬁn embedded, and frozen in liquid
nitrogen. The ﬁrst complete cut from both halves was
stained with hematoxylin and eosin (H&E) and examined
for the presence of metastases by the pathologist. The
result of the FS analysis was reported to the operating
surgeon a median 22 min after removal of the axillary
SLNs and usually before the surgery for the primary breast
tumor was completed. If FS conﬁrmed the presence of
metastases in the SLN, an ALND was done. An ALND
consisted of the removal of all axillary fat from levels I and
II and as much as from level III as could be obtained
through the axillary incision.
Postoperatively, the remaining tissue of the axillary
SLNs and IM SLNs were ﬁxated in formalin and embedded
in parafﬁn. The presence of lymph node metastases was
investigated by examining 5 cuts from both halves of the
node, 250 lm apart, with H&E and immunohistochemical
techniques staining for cytokeratin-8 (IHC). The examining
pathologist assessed tumor diameter, the adjusted Bloom
Richardson grade (BR-grade), Mitotic Activity Index
(MAI), hormonal receptor status (estrogen receptor (ER),
and progesterone receptor (PR)) for all patients and HER2/
neu status from 2004 on.
7 The presence of lymph node
metastases was classiﬁed according to the 2002 version of
the UICC-TNM-classiﬁcation.
8
When the intraoperative FS did not show metastases but
the deﬁnitive histology did reveal lymph node metastases,
patients were advised to undergo a second operation to
perform a complementary ALND. Lymph nodes from the
complementary ALND specimen were ﬁxated in formalin,
embedded in parafﬁn, and 2 cuts from the center of the
node were examined after staining with H&E and IHC.
The indication for subsequent nonsurgical treatment was
determined applying the Dutch national guidelines (2008,
version 1.1).
9 In summary: (1) Adjuvant systemic chemo-
therapy is advocated in patients younger than 70 years and
in the presence of lymph node (macro) metastases, or when
the tumor diameter exceeds 2 cm, or when the tumor is
larger than 1 cm and the BR grade is II or III. (2) Adjuvant
hormonal therapy is advocated under similar conditions,
given ER-positive status of the tumor, but irrespective of
age. (3) Radiotherapy other than as part of breast-con-
serving therapy and irrespective of tumor size is indicated
when C 4 axillary lymph nodes or level III axillary lymph
nodes contain metastases. Locoregional radiotherapy is
then advocated. When IM SLNs contain metastases (and
axillary SLNs not) radiotherapy of the parasternal and
midclavicular ﬁeld is indicated. Follow-up started at the
date of the ﬁrst operative procedure. Dates of death and
locoregional recurrence were recorded prospectively until
the last patient visit between October 2007 and May 2008.
The frequency of a ‘‘positive’’ FS result, that is, SLN
metastases present, and the frequency of discordance
between the intraoperative FS result ‘‘no metastasis’’ and
the ﬁnding of lymph node metastases in the formalin-ﬁx-
ated and cytokeratin-stained additional cuts of the SLN
were assessed. The metastatic burden in the 2 groups,
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using chi-square analysis.
Then, for patients who underwent a postponed ALND
after a discordant FS result, the proportion of patients with
additional lymph node metastases was analyzed as well as
the proportion of these latter patients with an increased
TNM N class. The advice for subsequent nonsurgical
treatment was determined after the ﬁrst operation and again
after the postponed ALND, and we evaluated how often the
complementary ALND led to adjustment of nonsurgical
treatment.
Lastly, we compared cumulative overall survival and the
occurrence of locoregional relapses for the 3 groups
delineated by the FS and the deﬁnitive pathology exami-
nation result.
RESULTS
The median age of the 879 patients was 60 years (range
24–92); the clinicopathologic characteristics are summa-
rized in Table 1. In addition to the axillary SLNs that were
removed in all patients inherent to the selection of patients,
IM SLNs were visualized on the preoperative lympho-
scintigraphy in 193 patients. These IM SLNs were
successfully removed in 157 (81%) of the patients.
Axillary lymph node metastases were detected in 359
patients: in the SLN by intraoperative FS (n = 200), in the
SLN after the deﬁnitive pathology examination (discordant
FS result; n = 151), in an axillary, non-SLN, not examined
by FS (n = 4), or within the removed breast tissue, that is,
intramammary (n = 4). Also, 42 patients had IM lymph
node metastases (27%), usually in combination with axil-
lary metastases. Isolated IM metastases were found in 9
patients. A total of 511 patients (58%) had no lymph node
metastases.
Intraoperative FS analysis detected axillary metastases
in 200 patients (23%). See Fig. 1. In these patients, a direct
complementary ALND revealed additional metastases in
101 patients (51%). Deﬁnitive lymph node status was
classiﬁed as: N1mi (n = 10), N1 (n = 133), C N2/N3
(n = 57). See Table 2.
In 151 patients the FS result was discordant with the
result of the deﬁnitive pathology examination: axillary
lymph node metastases were found only after the deﬁnitive
examination of the serial sectioned lymph nodes (17%). A
second operation to perform a complementary ALND was
not done in 39 of them (26%) for various reasons: age or
frailty of the patient (n = 25), an already existing indica-
tion for parasternal radiotherapy due to metastases in IM
SLNs (n = 5), a synchronous contralateral breast cancer
with preoperatively proven lymph node metastases
(n = 2), or unknown (n = 7).
In the 112 patients who underwent ALND as a sec-
ondary operation because of discordance between FS and
deﬁnitive pathology examination of the SLN, the patho-
logical ﬁndings of the ALND specimen revealed additional
lymph node metastases in 17 patients (15%). Compared
TABLE 1 Clinicopathologic characteristics of the patients
Characteristic No. (%)
Patients (n) 879 (100)
Age (years): median (range) 59.6 (24.2–92.1)
Tumor size (cm)
\1 106 (12)
1–2 461 (52)
2–3 231 (26)
[3 74 (8)
Unknown 7 (1)
Deﬁnitive nodal status
N0 511 (58)
Nitc 24 (3)
N1micro 95 (11)
N1a 158 (18)
N1b 9 (1)
N1c 20 (2)
N2a 38 (4)
N3a 17 (2)
N3b 7 (1)
Bloom Richardson grade
1 368 (42)
2 337 (38)
3 164 (19)
Unknown 10 (1)
Estrogen receptor status
Positive 759 (86)
Negative 119 (14)
Unknown 1 (0)
Progesterone receptor status
Positive 584 (66)
Negative 293 (34)
Unknown 2 (0)
HER2/neu status
Positive 75 (9)
Negative 667 (76)
Unknown
a 137 (15)
Histopathologic type
Ductal 744 (85)
Lobular 108 (12)
Tubular 9 (1)
Other 14 (2)
Unknown 4 (0)
a Before 2004, HER2/neu status was not routinely analyzed
2692 D. Geertsema et al.with the group of patients with ‘‘positive’’ FS results, the
metastatic burden in the regional lymph nodes was sig-
niﬁcantly less in the group with discordant FS results
(P\.001; Table 2).
The ﬁnding of additional lymph node metastases in 17
patients resulted in a higher UICC TNM N class in seven
patients (6%, Table 3). When applying the Dutch national
guidelines, the ﬁndings of the subsequent ALND resulted
in adjustment of subsequent nonsurgical treatment in 4
patients (4%). These 4 patients were advised to receive
more extensive locoregional radiotherapy. No patient
would have received additional hormonal and/or chemo-
therapy based on the complementary ALND (Table 4).
After a median follow-up of 40 months the estimated
cumulative 5-year overall survival was 90% in the group of
patients with a discordant FS result, compared with 94% in
the group who had no axillary metastases and 80% in the
group who had metastases that were detected by FS anal-
ysis (P\.001; log-rank test). At the end of follow-up,
locoregional relapses had been detected in 1 (0.7%), 4
(0.8%) and 6 patients (3%), respectively. None of the 39
patients who had metastases in the SLN but did not
undergo a postponed ALND developed an axillary relapse.
DISCUSSION
In this prospective cohort of breast cancer patients,
discrepancy between ‘‘negative’’ frozen section analysis
and the deﬁnitive pathology examination of SLNs was
common, occurring in 17% of all patients and in almost
half of the patients with lymph node metastases. In this
selection of patients, an ALND as a secondary operation
revealed additional metastases in 17% of the patients,
inﬂuencing subsequent radiotherapy in a small proportion
of patients. Adjuvant systemic treatment (hormonal and/or
chemotherapy) was not adjusted.
The present study describes a large cohort of consecutive
breast cancer patients operated since the introduction of the
SLNB in our hospital. Despite the volume of the overall
group,thecohortofinterest(i.e.,theselectionof151patients
with discordant FS results in whom ALND as a second
operation was indicated) was still modest. In addition, lim-
iting the study group and introducing a potential source of
selection bias, a substantial number of patients had no
complementary ALND after the discordant FS result.
Discordance between FS analysis and the deﬁnitive
pathology result was common, occurring in 17% of the
patients operated for cT1–2N0 breast cancer. In itself, this
is not surprising since serial sectioning will reveal the
smaller metastases that go unnoticed when examining 2
cuts from the center of a lymph node when intraoperative
frozen section analysis is done. As one would expect,
discrepancy between frozen section and deﬁnitive pathol-
ogy examination was strongly related to minimal lymph
node involvement.
3,10–12 Apparently, FS analysis can dis-
criminate reliably between gross and limited (or no)
metastatic lymph node involvement.
Many studies have addressed the chances of addi-
tional non-SLN lymph node metastases in patients with
Breast cancer surgery and
sentinel lympyh node biopsy
(n = 1004)
No frozen section analysis
(n = 125)
Frozen section analysis of
axillary sentinel lymph node
(n = 879)
Frozen section –/definitive
pathology result: metastases +
(n = 151)
Complementary axillary
lymph node dissection
(n = 112)
*17 patients had regional lymph node
  metastases, see text results for explanation.
Frozen section: metastases +
(n = 200)
Frozen section: metastases –
(n = 679)
Frozen section –/definitive
pathology result: metastases –
(n = 528*)
FIG. 1 Summary of axillary lymph node staging
TABLE 2 Metastatic lymph node involvement (UICC-TNM N
classes) in relation to the detection of metastases by frozen section
analysis or after deﬁnitive pathology examination of the sentinel
lymph node
N stage FS: metastases ?
n = 200
a
FS: metastases -/
deﬁnitive PA: metastases ?
n = 151
a
P*
Nitc – 24 (16) \.001
N1mi 10 (5) 84 (56)
N1a 122 (61) 31 (21)
N1c 11 (6) 8 (5)
N2a 33 (17) 4 (3)
N3a 17 (9) –
N3b 7 (4) –
Values in parentheses are percentages. Deﬁnitive N status as deter-
mined after deﬁnitive surgery, including the ﬁndings in the IM SLNs
a 3 patients in the FS ? group and 39 patients in the other group did
not have an ALND; N class was based on the examination of the
SLN(s). See text results
* Chi-square analysis
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with discordance between the FS and deﬁnitive pathology
result had micrometastases in their SLNs, the observed
frequency of additional metastases following the postponed
ALND is unsurprisingly similar to the reported proportions
of non-SLN metastases in patients with SLNs with mi-
crometastases.
3,4 Observing additional metastases in
approximately 15% of the patients who underwent a
postponed ALND, most authors underline the importance
of a complementary ALND.
4,13
No studies, to our knowledge, investigated the clinical
consequences of the ALND in the selection of patients who
had discordant frozen section results. In this selection of
patients the metastatic lymph node involvement is limited
and remains so after the postponed ALND. While addi-
tional metastases were quite common, extra adjuvant
systemic treatment was never advised, while more exten-
sive (locoregional) radiotherapy was proposed in less than
5% of the patients. These very limited clinical implications
of the postponed ALND were surprising. Then again,
recent data suggest that even limited lymph node
involvement has an adverse prognostic effect on outcome,
and the authors advocate adjuvant systemic therapy in all
patients with micrometastases and isolated tumor cells.
14 In
that perspective, a postponed ALND would by deﬁnition
have no effect on systemic therapy.
In contrast to the limited implications of the ALND after
a discordant FS result, extensive metastatic lymph node
involvement, that is, TNM class N2 or N3, was found in
more than one-quarter of the patients when FS analysis
revealed lymph node metastases intraoperatively, and
ALND was done instantly. This necessitated extension of
the radiotherapy ﬁeld and potentially led to more intensive
chemotherapy in a similar proportion.
The primary objective of intraoperative FS analysis of
axillary SLNs is sparing patients a second operative pro-
cedure. In addition, the present data demonstrate that when
there is discrepancy between a negative FS analysis and a
tumor-positive deﬁnitive pathology result, the ALND is
merely advised for locoregional control decreasing the risk
of axillary recurrence in the future by removing additional
metastases in non-SLNs in a substantial proportion of
patients and by necessitating extension of the radiotherapy
treatment in a small proportion of patients. However,
TABLE 3 N class adjustment as the result of complementary ALND in patients with discordant FS results of SLNs (n = 7)
Patient
No.
Tumor positive
axillary SLNs (n)
Diameter of axillary
metastasis (mm)
Tumor positive
IM SLNs (n)
N class after
1st surgery
Extra tumor positive
LNs after ALND
Deﬁnitive N class
after ALND
1 2 1.1 0 N1mi ?1N 1mi ? N1a
2 1 0.7 0 N1mi ?1N 1mi ? N1a
3 1 1.3 0 N1mi ?2N 1mi ? N1a
41 [20 N 1a ?5N 1a ? N2a
52 [20 N 1a ?3N 1a ? N2a
6 1 3.5 0 N1a ?3N 1a ? N2a
72 [20 N 1a ?2N 1a ? N2a
SLNs sentinel lymph nodes, ALND axillary lymph node dissection, LNs lymph nodes, IM internal mammary chain
TABLE 4 Adjustment of subsequent nonsurgical treatment in patients with a higher N class after the complementary ALND following
discordant FS results of SLNs (n = 7)
Patient
(No.)
Age
(y)
Deﬁnitive N stage
after ALND
Tumor characteristics Proposed postsurgical treatment
after ﬁrst operation (SNB and FS)
Deﬁnitive treatment after
second operation (ALND)
Tumor
size (cm)
HER2/neu ER/PR BR
grade
RT CT (Y/N) HT (Y/N) Treatment adjustment?
17 7 N 1mi ? N1a 4.8 – -/- 3N o N o N o N o
24 3 N 1mi ? N1a 2.3 – -/- 2 loco Yes No No
36 2 N 1mi ? N1a 6– ?/? 1 prot Yes Yes No
45 7 N 1a ? N2a 2.1 U ?/- 1 No Yes Yes Yes, loco RT
54 6 N 1a ? N2a 2.2 – ?/- 1 No Yes Yes Yes, loco RT
67 5 N 1a ? N2a 1.1 – ?/? 2 No No Yes Yes, loco RT
74 9 N 1a ? N2a 2.1 – ?/? 1 prot Yes Yes Yes, loco RT
SNB sentinel node biopsy, FS frozen section, ALND axillary lymph node dissection, RT radiotherapy, loco locoregional, prot according to
protocol, CT chemotherapy, HT hormonal therapy, BR Bloom-Richardson grade, ER/PR estrogen–progesterone receptor status, U unknown
2694 D. Geertsema et al.ALND as a procedure to improve locoregional control has
been under debate well before the era of the SLN proce-
dure. This makes the case for routine ALND in this
category of patients with very limited metastatic lymph
node involvement questionable.
15
Radiotherapy of the axilla is currently under investiga-
tion in a randomized trial (EORTC 10981 AMAROS trial),
evaluating the role of radiotherapy as a substitute for
ALND in patients with metastases-containing SLNs.
5 If
this trial will document similar locoregional control rates,
radiotherapy will be a proper alternative for axillary
treatment that will probably be preferred by many women
and clinicians. In patients with gross metastatic lymph node
involvement, ALND may still be desirable to obtain opti-
mal staging information that will inﬂuence nonsurgical
treatment in a one-quarter of the patients. When metastases
are only detected by the deﬁnitive pathology examination,
ALND will very rarely lead to postsurgical treatment
changes. These latter patients will be very good candidates
for radiotherapy to the axilla obviating the need for a
postponed ALND.
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